Razafintsalama T, Coiffic J, Godin O, Lassel L, Chevrant-Breton O, Poulain P
Chef de clinique, CHU de Rennes, Cedex.
J Gynecol Obstet Biol Reprod (Paris). 2000 Apr;29(2):176-84.
To determine the interest of percutaneous umbilical blood sampling in maternal thrombocytopenia.
We performed a retrospective study of 36 percutaneous umbilical samples in pregnant women with thrombocytopenia. We included patients with a platelet count less than 100,000/mm(3) or a previous diagnosis of idiopathic thrombocytopenic purpura. Patients were divided into two groups. Group A consisted of women whose thrombocytopenia was caused by idiopathic thrombocytopenic purpura. The other patients were included in the group B. Percutaneous umbilical blood samples were performed by direct ultrasound guidance under sterile conditions, after 37 weeks gestation. Cesarean section was indicated if the fetal platelet count was < or =50 000/mm(3), in other cases obstetric indications were followed.
Percutaneous umbilical blood samples were performed at a mean age of 38.5 gestational weeks. Fetal blood sampling was successful in 34 of the 36 cases. There was no fetal complication. In group A, two fetuses had low cord-blood platelet counts (20,000 and 98,000 per cubic millimeter). There was no fetal thrombopenia in group B. Three cesarean sections were performed, in one case because of severe fetal thrombocytopenia and in 2 cases because of an unsuccessful percutaneous umbilical blood sampling (in both, neonatal platelet count was normal). There was no significant complication in infants. There was a significant correlation between fetal and neonatal platelet count.
There is no maternal predictive factor for fetal thrombocytopenia. Percutaneous umbilical blood sampling is feasible and has a good diagnostic value. The overall risk of fetal loss is low. But there is no indication of percutaneous umbilical blood sampling in the management of thrombocytopenia in pregnancy because severity of thrombopenia is not directly related to the severity of maternal disease and there are no series large enough to assess the association between delivery method and intracranial hemorrhage in thrombocytopenic infants born of mothers with idiopathic thrombocytopenic purpura. More subjectively than on scientific arguments a percutaneous umbilical blood sampling could be performed for patients with idiopathic thrombocytopenia purpura and a past history of neonatal intracranial hemorrhage. A cesarean section could be done if the platelet count is less than 100 000/mm(3), no intracranial hemorrhage has been described above this level.
确定经皮脐血采样在孕产妇血小板减少症中的应用价值。
我们对36例血小板减少症孕妇的经皮脐血采样进行了回顾性研究。纳入血小板计数低于100,000/mm³或既往诊断为特发性血小板减少性紫癜的患者。患者分为两组。A组为血小板减少症由特发性血小板减少性紫癜引起的女性。其他患者纳入B组。妊娠37周后,在无菌条件下经直接超声引导进行经皮脐血采样。若胎儿血小板计数≤50,000/mm³,则行剖宫产,其他情况则遵循产科指征。
经皮脐血采样时的平均孕周为38.5周。36例中有34例胎儿血样采集成功。无胎儿并发症。A组中有2例胎儿脐血血小板计数较低(每立方毫米20,000和98,000)。B组无胎儿血小板减少症。共进行了3次剖宫产,1例是因为严重胎儿血小板减少症,2例是因为经皮脐血采样失败(这两例新生儿血小板计数均正常)。婴儿无明显并发症。胎儿与新生儿血小板计数之间存在显著相关性。
对于胎儿血小板减少症,不存在母体预测因素。经皮脐血采样可行且具有良好的诊断价值。胎儿丢失的总体风险较低。但在妊娠血小板减少症的管理中,不建议进行经皮脐血采样,因为血小板减少的严重程度与母体疾病的严重程度无直接关系,且没有足够大的系列研究来评估分娩方式与特发性血小板减少性紫癜母亲所生血小板减少症婴儿颅内出血之间的关联。对于有特发性血小板减少性紫癜且有新生儿颅内出血既往史的患者,经皮脐血采样可能更多是基于主观因素而非科学依据。若血小板计数低于100,000/mm³且在此水平以上未描述有颅内出血,则可进行剖宫产。